Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: A two-tier monolayer in vitro study

Pharmaceutical Research

Volumn 28, Issue 10, 2011, Pages 2575-2588

  Tsume, Yasuhiro ^a   Hilfinger, John M ^b   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TSRL INC   (United States)

Author keywords

antiproliferative action; Capan 2 pancreatic cancer cells; in vitro tumor model; mono amino acid and dipeptide monoester floxuridine prodrugs; permeation and bioactivation; prodrug cocktail; two tier Capan 2 monolayer; two tier Capan 2 pancreatic cancer monolayer

Indexed keywords

5' O DEXTRO PHENYLALANYLFLOXURIDINE; 5' O DEXTRO VALYLFLOXURIDINE; 5' O GLYCYLFLOXURIDINE; 5' O GLYCYLLEUCYLFLOXURIDINE; 5' O ISOLEUCYLFLOXURIDINE; 5' O ISOLEUCYLGLYCYLFLOXURIDINE; 5' O LEUCYLFLOXURIDINE; 5' O LEUCYLGLYCYLFLOXURIDINE; 5' O LYSYLFLOXURIDINE; 5' O PHENYLALANYLFLOXURIDINE; 5' O PHENYLALANYLGLYCYLFLOXURIDINE; 5' O PHENYLALANYLTYROSYLFLOXURIDINE; 5' O VALYLFLOXURIDINE; 5' O VALYLPHENYLALANYLFLOXURIDINE; AMINO ACID PRODRUG; DIPEPTIDE PRODRUG; FLOXURIDINE; FLUOROURACIL; PRODRUG; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; ENZYMATIC DEGRADATION; IN VITRO STUDY; MONOLAYER CULTURE; NONHUMAN; PH; PRIORITY JOURNAL;

AMINO ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DIPEPTIDES; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENZYME STABILITY; FLOXURIDINE; HUMANS; NEOPLASMS; PERMEABILITY; PRODRUGS;

EID: 80054752014     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0485-7     Document Type: Article

References (66)

1. MA Bookman 1995 Biologic therapies for gynecologic cancer Curr Opin Oncol 7 478 484 8541395 10.1097/00001622-199509000-00015 1:STN:280: DyaK28%2Fns1artw%3D%3D
2. J Gray C Frith J Parker 2000 In vivo enhancement of chemotherapy with static electric or magnetic fields Bioelectromagnetics 21 575 583 11102947 10.1002/1521-186X(200012)21:8<575::AID-BEM3>3.0.CO;2-F 1:STN:280:DC%2BD3M7gtFOltA%3D%3D
3. D Kamstock A Guth R Elmslie I Kurzman D Liggitt L Coro, et al. 2006 Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma Cancer Gene Ther 13 306 317 16138118 10.1038/sj.cgt.7700895 1:CAS:528:DC%2BD28Xhtl2msbY%3D (Pubitemid 43255768)
4. T Keler S Khan S Sorof 1997 Liver fatty acid binding protein and mitogenesis in transfected hepatoma cells Adv Exp Med Biol 400A 517 524 9547599 1:CAS:528:DyaK1cXjs12iur4%3D
5. F Kratz A Mansour J Soltau A Warnecke I Fichtner C Unger, et al. 2005 Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen Arch Pharm (Weinheim) 338 462 472 10.1002/ardp. 200500130 1:CAS:528:DC%2BD2MXht1WntLrJ (Pubitemid 41564256)
6. M Kullberg K Mann JL Owens 2005 Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors Med Hypotheses 64 468 470 15617850 10.1016/j.mehy.2004.07.033 1:CAS:528: DC%2BD2cXhtFGhsrjM (Pubitemid 40023003)
7. S Mittal X Song BS Vig CP Landowski I Kim JM Hilfinger, et al. 2005 Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs Mol Pharm 2 37 46 15804176 10.1021/mp049922p 1:CAS:528:DC%2BD2MXmsVSrtg%3D%3D (Pubitemid 40314728)
8. E Wagner R Kircheis GF Walker 2004 Targeted nucleic acid delivery into tumors: new avenues for cancer therapy Biomed Pharmacother 58 152 161 15082337 10.1016/j.biopha.2004.01.003 1:CAS:528:DC%2BD2cXjtV2gsL0%3D (Pubitemid 38479919)
9. N Shimma I Umeda M Arasaki C Murasaki K Masubuchi Y Kohchi, et al. 2000 The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine Bioorg Med Chem 8 1697 1706 10976516 10.1016/S0968-0896(00)00087-0 1:CAS:528:DC%2BD3cXkvVyksLs%3D (Pubitemid 30427234)
10. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori, et al. 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281 9849491 10.1016/S0959-8049(98)00058-6 1:CAS:528:DyaK1cXltlCgsrk%3D (Pubitemid 28342121)
11. HM Pinedo GF Peters 1988 Fluorouracil: biochemistry and pharmacology J Clin Oncol 6 1653 1664 3049954 1:CAS:528:DyaL1MXotA%3D%3D
12. JL Grem N Harold J Shapiro DQ Bi MG Quinn S Zentko, et al. 2000 Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors J Clin Oncol 18 3952 3963 11099325 1:CAS:528:DC%2BD3cXptVSiu70%3D
13. JD Laskin RM Evans HK Slocum D Burke MT Hakala 1979 Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture Cancer Res 39 383 390 761209 1:CAS:528:DyaE1MXhtlaltbg%3D (Pubitemid 9095896)
14. Y Tsume JM Hilfinger GL Amidon 2008 Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability Mol Pharm 5 717 727 18652477 10.1021/mp800008c 1:CAS:528:DC%2BD1cXovFSkurc%3D
15. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
16. M Barton-Burke 1999 Gemcitabine: a pharmacologic and clinical overview Cancer Nurs 22 176 183 10217035 10.1097/00002820-199904000-00011 1:STN:280:DyaK1M3jt1Krsw%3D%3D (Pubitemid 29352696)
17. V Heinemann LW Hertel GB Grindey W Plunkett 1988 Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine Cancer Res 48 4024 4031 3383195 1:CAS:528:DyaL1cXlt1ajurc%3D
18. W Plunkett P Huang V Gandhi 1995 Preclinical characteristics of gemcitabine Anticancer Drugs 6 Suppl 6 7 13 8718419 10.1097/00001813-199512006- 00002 1:CAS:528:DyaK28XlsFyksg%3D%3D (Pubitemid 26014890)
19. W Plunkett P Huang YZ Xu V Heinemann R Grunewald V Gandhi 1995 Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 3 10 7481842 1:CAS:528:DyaK2MXpsFGntbY%3D
20. Y Tsume BS Vig J Sun CP Landowski JM Hilfinger C Ramachandran, et al. 2008 Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters Molecules 13 1441 1454 18719516 10.3390/molecules13071441 1:CAS:528:DC%2BD1cXpt1Ghsr0%3D
21. CP Landowski BS Vig X Song GL Amidon 2005 Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs Mol Cancer Ther 4 659 667 15827340 10.1158/1535-7163.MCT-04-0290 1:CAS:528:DC%2BD2MXjtFegsLk%3D (Pubitemid 40601848)
22. X Song PL Lorenzi CP Landowski BS Vig JM Hilfinger GL Amidon 2005 Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport Mol Pharm 2 157 167 15804190 10.1021/mp049888e 1:CAS:528:DC%2BD2MXitlKgtr4%3D (Pubitemid 41295363)
23. I Behrens W Kamm AH Dantzig T Kissel 2004 Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin J Pharm Sci 93 1743 1754 15176063 10.1002/jps.20062 1:CAS:528: DC%2BD2cXltlKrsrg%3D (Pubitemid 38823702)
24. GD Geromichalos DT Trafalis GA Katsoulos A Papageorgiou P Dalezis EB Triandafillidis, et al. 2006 Synergistic interaction between a mixed ligand copper (II) chelate complex and two anticancer agents in T47D human breast cancer cells in vitro J BUON 11 469 476 17309179 1:STN:280: DC%2BD2s7htVSjug%3D%3D (Pubitemid 46729861)
25. M Ohbayashi M Yasuda I Kawakami N Kohyama Y Kobayashi T Yamamoto 2008 Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells Exp Oncol 30 276 282 19112424 1:CAS:528:DC%2BD1MXjtFKntbY%3D
26. JM Padron CL van der Wilt K Smid E Smitskamp-Wilms HH Backus PE Pizao, et al. 2000 The multilayered postconfluent cell culture as a model for drug screening Crit Rev Oncol Hematol 36 141 157 11033303 10.1016/S1040-8428(00) 00083-4 1:STN:280:DC%2BD3M%2FotFSjtA%3D%3D
27. W Rubas N Jezyk GM Grass 1995 Mechanism of dextran transport across rabbit intestinal tissue and a human colon cell-line (CACO-2) J Drug Target 3 15 21 7544676 10.3109/10611869509015928 1:CAS:528:DyaK2MXls1yju7k%3D
28. R Zhao TJ Raub GA Sawada SC Kasper JA Bacon AS Bridges, et al. 2009 Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier Drug Metab Dispos 37 1251 1258 19273529 10.1124/dmd.108.025064 1:CAS:528: DC%2BD1MXmslamu7g%3D
29. JL Au SH Jang J Zheng CT Chen S Song L Hu, et al. 2001 Determinants of drug delivery and transport to solid tumors J Control Release 74 31 46 11489481 10.1016/S0168-3659(01)00308-X 1:CAS:528:DC%2BD3MXlslansr8%3D (Pubitemid 32727607)
30. AI Minchinton IF Tannock 2006 Drug penetration in solid tumours Nat Rev Cancer 6 583 592 16862189 10.1038/nrc1893 1:CAS:528:DC%2BD28XntFGlu7w%3D (Pubitemid 44140857)
31. I Rizvi JP Celli CL Evans AO Abu-Yousif A Muzikansky BW Pogue, et al. 2010 Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer Cancer Res 70 9319 9328 21062986 10.1158/0008-5472.CAN-10-1783 1:CAS:528:DC%2BC3cXhsVWmsLjJ
32. T Ohmori JL Yang JO Price CL Arteaga 1998 Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy Exp Cell Res 245 350 359 9851876 10.1006/excr.1998.4261 1:CAS:528:DyaK1cXotVWqsb8%3D (Pubitemid 28565777)
33. SV Sharma DA Haber J Settleman 2010 Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat Rev Cancer 10 241 253 20300105 10.1038/nrc2820 1:CAS:528:DC%2BC3cXjsFWjsrw%3D
34. MG del Carmen I Rizvi Y Chang AC Moor E Oliva M Sherwood, et al. 2005 Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo J Natl Cancer Inst 97 1516 1524 16234565 10.1093/jnci/dji314 (Pubitemid 41631951)
35. KL Molpus D Kato MR Hamblin L Lilge M Bamberg T Hasan 1996 Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model Cancer Res 56 1075 1082 8640764 1:CAS:528: DyaK28XhtlKktr4%3D (Pubitemid 26065403)
36. JC Finlay S Mitra MS Patterson TH Foster 2004 Photobleaching kinetics of Photofrin in vivo and in multicell tumour spheroids indicate two simultaneous bleaching mechanisms Phys Med Biol 49 4837 4860 15584523 10.1088/0031-9155/49/ 21/001 1:CAS:528:DC%2BD2cXhtVGqu7%2FE (Pubitemid 39489928)
37. J Friedrich R Ebner LA Kunz-Schughart 2007 Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge? Int J Radiat Biol 83 849 871 18058370 10.1080/09553000701727531 1:CAS:528:DC%2BD2sXhtl2is7fL (Pubitemid 350219104)
38. KM Yamada E Cukierman 2007 Modeling tissue morphogenesis and cancer in 3D Cell 130 601 610 17719539 10.1016/j.cell.2007.08.006 1:CAS:528: DC%2BD2sXhtVels77F (Pubitemid 47268064)
39. JL Horning SK Sahoo S Vijayaraghavalu S Dimitrijevic JK Vasir TK Jain, et al. 2008 3-D tumor model for in vitro evaluation of anticancer drugs Mol Pharm 5 849 862 18680382 10.1021/mp800047v 1:CAS:528:DC%2BD1cXptlejs7o%3D
40. LA Kunz-Schughart JP Freyer F Hofstaedter R Ebner 2004 The use of 3-D cultures for high-throughput screening: the multicellular spheroid model J Biomol Screen 9 273 285 15191644 10.1177/1087057104265040 1:CAS:528: DC%2BD2cXls1Shtb0%3D
41. JB Kim 2005 Three-dimensional tissue culture models in cancer biology Semin Cancer Biol 15 365 377 15975824 10.1016/j.semcancer.2005.05.002 (Pubitemid 41149083)
42. JP Celli I Rizvi CL Evans AO Abu-Yousif T Hasan 2010 Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model J Biomed Opt 15 051603 21054077 10.1117/1.3483903
43. J Debnath JS Brugge 2005 Modelling glandular epithelial cancers in three-dimensional cultures Nat Rev Cancer 5 675 688 16148884 10.1038/nrc1695 1:CAS:528:DC%2BD2MXpsleksL0%3D (Pubitemid 41486361)
44. A Monazzam R Josephsson C Blomqvist J Carlsson B Langstrom M Bergstrom 2007 Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer Breast Cancer Res 9 R45 17659092 10.1186/bcr1747 (Pubitemid 350187476)
45. CP Landowski X Song PL Lorenzi JM Hilfinger GL Amidon 2005 Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism Pharm Res 22 1510 1518 16132363 10.1007/s11095-005- 6156-9 1:CAS:528:DC%2BD2MXptVWlurk%3D (Pubitemid 41215891)
46. BS Vig PJ Lorenzi S Mittal CP Landowski HC Shin HI Mosberg, et al. 2003 Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis Pharm Res 20 1381 1388 14567631 10.1023/A:1025745824632 1:CAS:528:DC%2BD3sXnt1Kitbo%3D (Pubitemid 37164045)
47. LM Beauchamp TA Krenitsky 1993 Acyclovir prodrugs: the road to valacyclovir Drugs Future. 18 619 628
48. LM Beauchamp GF Orr P De Miranda TC Burnette TA Krenitsky 1992 Amino acid ester prodrugs of acyclovir Antiviral Chem Chemother 3 157 164 1:CAS:528:DyaK38XltVelsbw%3D
49. Maag H. Ganciclovir pro-drugs: Synthesis and pre-clinical development of valganciclovir (Valcyte™)., AAPS Annual Meeting, Toronto, Canada., 2002.
50. DJ Purifoy LM Beauchamp P de Miranda P Ertl S Lacey G Roberts, et al. 1993 Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus J Med Virol Suppl 1 139 145 8245881 10.1002/jmv.1890410527 1:STN:280:DyaK2c%2FmsFKqtA%3D%3D (Pubitemid 23290500)
51. D Jung A Dorr 1999 Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects J Clin Pharmacol 39 800 804 10434231 10.1177/00912709922008452 1:CAS:528:DC%2BD3cXivFWrtA%3D%3D (Pubitemid 30629438)
52. MD Pescovitz J Rabkin RM Merion CV Paya J Pirsch RB Freeman, et al. 2000 Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients Antimicrob Agents Chemother 44 2811 2815 10991864 10.1128/AAC.44.10.2811-2815.2000 1:CAS:528:DC%2BD3cXmvVyqtLw%3D
53. ME Ganapathy W Huang H Wang V Ganapathy FH Leibach 1998 Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2 Biochem Biophys Res Commun 246 470 475 9610386 10.1006/bbrc.1998.8628 1:CAS:528:DyaK1cXjsFWiuro%3D (Pubitemid 28412626)
54. H Han RL de Vrueh JK Rhie KM Covitz PL Smith CP Lee, et al. 1998 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter Pharm Res 15 1154 1159 9706043 10.1023/A:1011919319810 1:CAS:528:DyaK1cXltFynsb4%3D (Pubitemid 28401703)
55. HK Han DM Oh GL Amidon 1998 Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter Pharm Res 15 1382 1386 9755889 10.1023/A:1011945420235 1:CAS:528: DyaK1cXmtFyhurw%3D (Pubitemid 28427925)
56. M Sugawara W Huang YJ Fei FH Leibach V Ganapathy ME Ganapathy 2000 Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2 J Pharm Sci 89 781 789 10824137 10.1002/(SICI)1520-6017(200006) 89:6<781::AID-JPS10>3.0.CO;2-7 1:CAS:528:DC%2BD3cXkt1artbY%3D
57. BS Anand J Patel AK Mitra 2003 Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2 J Pharmacol Exp Ther 304 781 791 12538834 10.1124/jpet.102.044313 1:CAS:528:DC%2BD3sXpvVClsg%3D%3D (Pubitemid 36152357)
58. AH Eriksson PL Elm M Begtrup R Nielsen B Steffansen B Brodin 2005 hPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives Mol Pharm 2 242 249 15934785 10.1021/mp050015+ 1:CAS:528:DC%2BD2MXjvFKju7s%3D (Pubitemid 40917421)
59. GM Friedrichsen W Chen M Begtrup CP Lee PL Smith RT Borchardt 2002 Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells Eur J Pharm Sci 16 1 13 12113886 10.1016/S0928-0987(02)00047-7 1:CAS:528:DC%2BD38XltFWit7Y%3D (Pubitemid 34756777)
60. D Meredith CS Temple N Guha CJ Sword CA Boyd ID Collier, et al. 2000 Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1 Eur J Biochem 267 3723 3728 10848990 10.1046/j.1432-1327.2000. 01405.x 1:CAS:528:DC%2BD3cXksVKgtb8%3D (Pubitemid 30423034)
61. CU Nielsen R Andersen B Brodin S Frokjaer ME Taub B Steffansen 2001 Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line J Control Release 76 129 138 11532319 10.1016/S0168-3659(01)00427-8 1:CAS:528: DC%2BD3MXmt1Gls74%3D (Pubitemid 32786891)
62. J Vabeno T Lejon CU Nielsen B Steffansen W Chen H Ouyang, et al. 2004 Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations J Med Chem 47 1060 1069 14761208 10.1021/jm031022+ 1:CAS:528:DC%2BD2cXksFyjsA%3D%3D (Pubitemid 38176809)
63. PL Lorenzi CP Landowski X Song KZ Borysko JM Breitenbach JS Kim, et al. 2005 Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl) benzimidazole enhance metabolic stability in vitro and in vivo J Pharmacol Exp Ther 314 883 890 15901797 10.1124/jpet.104.082412 1:CAS:528:DC%2BD2MXntVSitr4%3D (Pubitemid 41043875)
64. X Song BS Vig PL Lorenzi JC Drach LB Townsend GL Amidon 2005 Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D- ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter J Med Chem 48 1274 1277 15715497 10.1021/jm049450i 1:CAS:528:DC%2BD2MXosFWmuw%3D%3D (Pubitemid 40270473)
65. C Goolcharran RT Borchardt 1998 Kinetics of diketopiperazine formation using model peptides J Pharm Sci 87 283 288 9523979 10.1021/js970325m 1:CAS:528:DyaK1cXovFOgsg%3D%3D (Pubitemid 28204579)
66. SW Larsen M Ankersen C Larsen 2004 Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (Gly-Phe) Eur J Pharm Sci 22 399 408 15265509 10.1016/j.ejps.2004.04.013 1:CAS:528:DC%2BD2cXlsl2ntr4%3D (Pubitemid 38953898)